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Summary 
 
A wealth of recent data has shed light on the genetics of Parkinson’s disease. Mutations of 
specific genes have been discovered in a number of autosomal dominant and recessive forms of 
the disease, and polymorphisms in the same or other genes found to be associated with its 
occurrence in sporadic forms. Mutations in the gene encoding leucine-rich repeat kinase 2 
(LRRK2) cause an autosomal dominant form of Parkinson’s disease (PARK8) and have been 
found in patients with Parkinson’s disease with a highly variable frequency in different 
populations in the world. In this study we have examined the most common mutations so far 
described in this large gene:p.R1441C (together with p.R1441G and p.R1441H), p.Y1699C and 
p.G2019S. Seventy-three patients from Switzerland with Parkinson’s disease diagnosed 
according to Brain Bank criteria with the exception of positive family history were included in 
this study. The three exons, in which the above mutations had been found, were sequenced after 
amplification. There were no sequence differences compared with the published wild-type 
sequences in all patients. These data point at the low incidence of LRRK2 mutation in the Swiss 
(regions of Berne and Zurich) populations, similar to findings in other central European 
populations,but at great variance to Mediterranean populations. 
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Introduction 
 
Parkinson’s disease is a frequent disorder, 1% of people older than 60 years in Western countries 
are estimated to be affected, and the average age at onset is 60 [1].With an age of 85, the 
prevalence even increases to 4% [2]. Environmental factors, including industrial pollutants, 
farming, living in a rural area, drinking well water, pesticide and herbicide exposure and head 
trauma [3–9] have been associated with an increased risk to develop the disorder. The best-
established example of an environmental factor leading to Parkinson’s disease is MPTP, an 
oxidant present in artisanal drug preparations, which had caused an epidemic of the disorder in 
young patients in the eighties of the last century, and which is now commonly used to induce 
Parkinson’s disease in animal models [10]. Other non-genetic causes for Parkinson’s disease have 
been reviewed recently [11].  
However, a positive family history has consistently been reported as a strong risk factor 
for the disease [3, 12], and a large family from Grisons has been reported in the early literature in 
the field [13]. Up to 27% of patients with the disorder report a relative with Parkinson’s disease 
and up to 16% its presence in a parent or sibling. The risk of first degree relatives to get 
Parkinson’s disease is up to 9.5 times greater as compared to relatives of controls [8, 12, 14, 15]. 
In a large twin study monozygotic twin pairs with onset in at least one person before the age of 
50 had a significant higher risk of 6 times as compared to dizygotic twin pairs [16]. When the 
involvement of the dopaminergic function was examined using PET, the concordance in a group 
of 18 monozygotic twin pairs was significant at baseline, as compared to 16 dizygotic twin pairs 
[17].  Furthermore, the proportion became even higher in monozygotic twins during follow-up 
[17]. In a more recent study similarity for age at onset among sibling pairs with Parkinson’s 
disease and the greater risk for biological relatives as compared to spouses have again supported 
the presence of a genetic component [18]. Risk of Parkinson’s disease was high in first relatives 
of both early and late-onset patients, the risk for siblings was increased only for those of early 
onset patients [19]. Other studies have started to examine the interaction between genetic and 
environmental factors. For example, there is a significant increase in risk in cases with positive 
family history and smoking [20].  
The strongest evidence for a genetic causation of Parkinson’s disease has come from the 
observation of families with a clear-cut autosomal dominant or recessive inheritance. The 
investigations in these families with the performance of linkage studies have allowed the 
discovery of different genes (table 1) [21, 22]; furthermore, additional loci are known, and in 
time more genes with mutation directly causing the disorder are expected to be discovered. 
α-synuclein was the first gene with mutations causing Parkinson’s disease [23] and a 
p.A53T was found in one large family of Italian origin and three smaller pedigrees from Greece 
[23]. Later a p.A30P [24] and a p.E46K [25] mutation were found in other families of German or 
Spanish origin, respectively. Duplication or triplication of the region containing the gene, or of 
individual exons was found in additional families [26], with dementia in addition to Parkinsonian 
features, and a more severe phenotype in patients with triplication [27], pointing at a gene dose 
effect with more prominent α-synuclein accumulation within neurons and subsequent loss of 
dopamine function. The p.A53T mutation was found in additional families of Greek and Italian 
origin, most probably related to the first one, however, a number of other studies could not find 
additional mutations of this gene [28–31]. Even considering the very low number of cases with α-
synuclein mutation, the discovery of this protein has greatly advanced our knowledge of the 
molecular pathophysiology of idiopathic Parkinson’s disease, Lewy body disease and other 
neurodegenerative disorders. This protein is also involved in cases without mutations, leading to 
the concept of synucleinopathies [32], including the definition of potential molecular therapeutic 
targets [33]. 
Mutations in the gene coding for parkin [34] were found later, first in Japanese patients 
with autosomal recessive early onset parkinsonism. A large number of additional mutations were 
found in many other populations studied, including more than 50 point mutations, as well as 
exonic rearrangements, duplications and deletions, accounting for half of familial cases and 70% 
of sporadic cases with age of onset younger than 20 years [35–37]. The search for parkin 
mutations can be considered in young patients with the disorder, or in those with an autosomal 
recessive inheritance. Following the discovery of missense and deletion mutations in families 
with recessive Parkinson’s disease [38], large-scales studies have examined the DJ-1 gene in 
other patients but only rare additional mutations have been found [39–43], suggesting that only 
1% of patients with early onset Parkinson’s disease may have a DJ-1 mutation. 
Two mutations were found in a novel gene PINK1 [44] in families with autosomal 
recessive juvenile-onset Parkinson’s disease. Later additional mutations, including frameshift, 
missense and truncating mutations were indentified [45–48], with a relative amount of 1–7% of 
patients with Parkinson’s disease of Caucasian origin [43], suggesting that PINK1 and parkin 
may be the most common genes in autosomal recessive and possibly also sporadic young-onset 
Parkinson’s disease. 
A p.I93M substitution found in exon 4 of ubiquitin carboxy-terminal hydrolase L1 
(UCHL1) has been reported in a German family [49]. This has led to the examination of the role 
of this enzyme in Parkinson’s disease, but, no further mutation has been found in numerous 
studies. 
Further loci have been mapped in additional families (table 1), and the discovery of the 
respective genes is expected to further advance our understanding of the molecular 
pathophysiology of the disease. It is of note that mutations in other genes, involved in 
neurodegenerative disorders other than Parkinson’s disease, may sometimes have presentations 
similar to this disorder. This includes frontotemporal dementia, some of the spinocerebellar 
ataxias, dystonia-parkinson syndrome and mitochondrial disorders. 
Finally, PARK8 has been found on chromosome 12p11.2–q13 in a Japanese family with 
autosomal dominant Parkinson’s disease with otherwise typical presentation similar to idiopathic 
Parkinson’s disease, including age at onset, laterality and good response to L-dopa. The 
overwhelming majority of cases have typical Lewy body pathology, but absence of Lewy bodies 
in rare cases [50, 51]. This locus has been confirmed in families from other ethnic origins [52] 
and shortly thereafter, several mutations in a novel gene encoding leucine-rich repeat kinase 2 
(LRRK2) cloned within this locus have been reported [52, 53]. Mutations in the LRRK2 account 
to about 13% of cases with autosomal dominant Parkinson’s disease [28], they are also found in a 
substantial number of sporadic cases [54].As an example of a local study we therefore examined 
the most commonly found LRRK2 mutations in a cohort of patients with Parkinson’s disease 
from Switzerland. 
 
 
Material and Methods 
Seventy-three consecutive patients with Parkinson’s disease were included.They had been 
examined at the Department of Neurology, University Hospital,Zurich (H.H.J.) or at the 
Neurology practice in downtown Berne (J.-M. B.) and were all of Caucasian origin.The study has 
been approved by the respective Ethics Committees of the Cantons of Zurich and Berne.The 
diagnosis had been made according to Brain Bank criteria, with the exception of positive family 
history as an exclusion criterion for idiopathic Parkinson’s disease, and all patients responded 
well to treatment with L-dopa or dopamine agonists. 
Blood was withdrawn and DNA extracted according to standard procedures using 
QIAGEN PCR purification kit. Following primer pairs were used: for exon 31, mutations 
R1441C, R1441G and R1441H: 5’-CTTCTGAAGTCTGCTAGTTTCT- 3’(forward) and 5’-
CGTTGGCACACATTTGGATG- 3’(reverse); for exon 35, mutation Y1699C: 5’-
GCTCAACAAGGTTGGGTGTT-3’(forward) and 5’-ATGCTTTCAGGGAGAGGTAAG-3’ 
(reverse); for exon 41, mutation G2019S: 5’- TTTTGATGCTTGACATAGTGGAC-3’(forward) 
and 5’-CACATCTGAGGTCAGTGGTTATC-3’ (reverse). Direct sequencing was performed 
after optimised PCR amplification using Big Dye Terminator ver.3.1 cycle (Applied Biosystems) 
on an ABI3100 Genetic Analyser and analysed with DNA Sequencing Analysis (ver.3.7) 
software (Applied Biosystems). 
 
 
Results 
The age of the patients varied from 49 to 81 years (mean 70), 43% were women and 17% had a 
positive family history. No mutation was detected in any of the three exons studied in any of the 
patients. No polymorphisms were found either. 
 
 
Discussion 
 
Our exploration in a preliminary small set of patients with idiopathic and familial Parkinson’s 
disease from Switzerland did not demonstrate the presence of any of the LRRK2 mutations most 
commonly found in similar or larger sets of patients from other countries. Due to the small size 
of the sample, we cannot exclude the presence of these mutations in PD patients from Swiss 
origin, but based on our data we can conclude that the frequency will most probably be in the 
lower range found in different populations. A high frequency of the p.G2019S mutation in 
sporadic Parkinson’s disease has been found in North African Arabs (20%) [55] and Ashkenazi 
Jews (13%) [56], where- as the same mutation was absent in Chinese PD patients [57]. About 7% 
of PD patients from cohorts of similar size as ours in the Iberic peninsula carried the mutation 
[58, 59], and a low prevalence of this mutation from 0 to 3% was documented in other European 
populations, like Poland [60], Norway [61] and Germany [28].The absence of this mutation in 
our set of patients is in line with the low frequency of the mutation in North and Middle 
European populations. As the penetrance of the p.G2019S mutation increases with age [54, 62] 
and the age of patients in our cohort is in the higher range, the absence of this mutation was not 
due to a selection bias of younger patients. Several mutations at position 1441 have been 
described earlier in different populations. The p.R1441H mutation has been found in rare families 
of different origins [59, 63–65]. In contrast, the p.R1441G mutation is quite frequent in PD 
patients from the Basque region [66]. 
LRRK2 codes for a protein with 2527 amino acids [52], which has a molecular mass of 
approximately 250–280 kDA [67, 68]. The gene is selectively expressed at high levels in the 
mouse [69], rat and human striatum [70], which is in contrast with the more widespread 
expression of other genes mutated in familial forms of Parkinson’s disease.The presence of 
specific domains,including ANK, LRR, Roc, COR, Kinase or MAPKKK, and WD40, suggests a 
role in signalling [52, 71]. The soluble protein is located in the cytoplasm [72], consistent with 
the absence of specific targeting signal, as demonstrated after HA-tagging in cell culture and 
immunohistochemistry in human brain sections [68]. Subcellular fractionation suggests a location 
close to mitochondria, microtubules, Golgi and endoplasmatic reticulum [73]. Interactions of 
LRRK2 have been demonstrated with parkin, but not with DJ-1, α-synuclein or tau [72]. 
Mutations of the protein do not consequently give rise to their accumulation [68], which is in 
contrast with the clear-cut pathophysiological mechanism of α-synuclein accumulation in 
hereditary and sporadic Parkinson’s disease. Functional analysis of one mutation, p.I2020T, 
located at the beginning of the kinase domain activation loop, led to the description of a 
significantly higher kinase activity, pointing at a gain-of-function for this particular mutation 
[73]. The p.R1441C, p.Y1699C and p.G2019S mutations, which we have studied in the present 
report, lead to neurodegeneration when expressed in specific cells in culture [72]. The p.R1441C 
mutation is localised within the GTPase domain, and the p.G2019S within the mixedkinase-like 
domain. Both mutations also lead to an increase in enzymatic activity, with increased substrate as 
well as auto-phosphorylation [67]. However, analysis of further mutations of this large protein 
with several domains will be needed to draw general conclusions about its physiological role and 
the biochemical changes induced by its mutations. 
Overall, there is a wide range of clinical presentations and neuropathological findings 
between the different mutations, and no clear-cut molecular–clinical correlation can be drawn so 
far. Although LRRK2 mutations may play a role in predisposing neurons to toxic effects, the 
exact nature of such epigenetic and environmental factors is not yet known. The high frequency 
of mutations in certain populations, both in familial and sporadic cases, indicates that this protein 
may play a key role in the pathogenesis of Parkinson’s disease. As the other proteins involved in 
the pathogenetic cascade in familial Parkinsonian syndromes, LRRK2 has the potential to deliver 
future drug targets for disease-modifying therapies. In order to advance in that direction, further 
data for clinical and molecular correlation are needed, as well as further studies in the biology of 
this protein. 
 
Table 
Selected genes and loci associated with Parkinson’s disease and parkinsonism 
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